Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 8.45
+0.40 (4.97%)
Sep 30, 2026, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 7.8 billion as of September 29, 2026. Its market cap has decreased by -34.57% in one year.
Market Cap
7.80B
Enterprise Value
6.45B
Revenue
598.06M
Ranking
n/a
PE Ratio
n/a
Stock Price
8.45
ChartMarket Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 7.80B, a decrease of -35.62%. That is a compound annual growth rate of -6.27%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 29, 2026 | 7.80B | -17.86% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Everest Medicines | 9.84B |
| Nanjing Leads Biolabs | 9.83B |
| Suzhou Ribo Life Science | 9.27B |
| CStone Pharmaceuticals | 8.85B |
| Ascletis Pharma | 8.77B |
| LongBio Pharma (Suzhou) | 7.47B |
| Lepu Biopharma | 7.43B |
| Shanghai Haohai Biological Technology | 7.23B |